Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula

被引:10
|
作者
Carano, Francesco [1 ]
Sarno, Stefania [2 ]
De Fanti, Sara [2 ]
Serventi, Patrizia [2 ,3 ]
Bini, Carla [1 ]
Luiselli, Donata [2 ]
Pelotti, Susi [1 ]
机构
[1] Univ Bologna, Inst Legal Med, Dept Med & Surg Sci, Bologna, Italy
[2] Univ Bologna, Dept Biol Geol & Environm Sci, Mol Anthropol Lab, Bologna, Italy
[3] Alma Mater Studiorum Univ Bologna, Dept Cultural Heritage, Ravenna, Italy
基金
欧洲研究理事会;
关键词
Pharmacogenetics; cytochrome-P450 (CYP) genes; Italian population; genetic variation; geographic structure; GENOTYPE; POLYMORPHISMS; VARIANTS; EXPRESSION; JAPANESE; ENZYMES; ALLELE; PCR;
D O I
10.1080/03014460.2017.1378368
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
Background: Environmental conditions and past migratory events may have shaped genetic heterogeneity of clinically relevant enzymes involved in the phase I metabolism of the most common therapeutic drugs.Aim: To investigate the genetic variability of CYP2D6, CYP2B6, CYP2C19 and CYP2C9 across the Italian Peninsula, by sampling only ancestrally and geographically homogeneous individuals from northern, central and southern Italy.Subjects and methods: A total of 25 SNPs were genotyped in 174 unrelated Italian individuals by means of multiplex PCR and minisequencing reactions. CYP2D6 genotypic data were used to predict phenotypes and the phylogenetic relationships among reconstructed haplotypes were represented by means of a Median Joining Network.Results: Pairwise Fisher Exact tests revealed significant differences between northern and southern Italy in the distribution of CYP2C19 genotypes, with the CYP2C19*2 allele appearing over-represented in northern Italy. Likewise, significant differences in the distribution of CYP2D6 genotypes (*4/*3, *4/*4 and *6/*4) responsible for the poor metabolizer phenotype were observed in northern with respect to both central and southern Italy.Conclusions: The north-south structuring pattern showed by CYP2D6 and CYP2C19 underline how a deeper knowledge of the geographic distribution of alleles may improve clinical practice and help to avoid hypothetical bias in drug trials.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [41] Genetic Polymorphisms of NAT2, CYP2C9, CYP2C19, CYP2D6 and CYP2E1, and Antituberculosis Drugs Induced Maculopapular Eruption
    Kim, S.
    Kim, S.
    Moon, J.
    Kim, T.
    Sohn, J.
    Yoon, H.
    Shin, D.
    Park, S.
    Jee, Y.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB357 - AB357
  • [42] Methodology for clinical genotyping of CYP2D6 and CYP2C19
    Henriques, Beatriz Carvalho
    Buchner, Avery
    Hu, Xiuying
    Wang, Yabing
    Yavorskyy, Vasyl
    Wallace, Keanna
    Dong, Rachael
    Martens, Kristina
    Carr, Michael S.
    Asl, Bahareh Behroozi
    Hague, Joshua
    Sivapalan, Sudhakar
    Maier, Wolfgang
    Dernovsek, Mojca Z.
    Henigsberg, Neven
    Hauser, Joanna
    Souery, Daniel
    Cattaneo, Annamaria
    Mors, Ole
    Rietschel, Marcella
    Pfeffer, Gerald
    Hume, Stacey
    Aitchison, Katherine J.
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [43] CYP2C19 and CYP2D6 genotypes in Pacific peoples
    Helsby, Nuala A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (05) : 1303 - 1307
  • [44] In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
    Xu, ZH
    Xie, HG
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (04) : 518 - 521
  • [45] Methodology for clinical genotyping of CYP2D6 and CYP2C19
    Beatriz Carvalho Henriques
    Avery Buchner
    Xiuying Hu
    Yabing Wang
    Vasyl Yavorskyy
    Keanna Wallace
    Rachael Dong
    Kristina Martens
    Michael S. Carr
    Bahareh Behroozi Asl
    Joshua Hague
    Sudhakar Sivapalan
    Wolfgang Maier
    Mojca Z. Dernovsek
    Neven Henigsberg
    Joanna Hauser
    Daniel Souery
    Annamaria Cattaneo
    Ole Mors
    Marcella Rietschel
    Gerald Pfeffer
    Stacey Hume
    Katherine J. Aitchison
    Translational Psychiatry, 11
  • [46] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity - Role of CYP2D6 and CYP2C19 in longevity
    Bathum, L
    Andersen-Ranberg, K
    Boldsen, J
    Brosen, K
    Jeune, B
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 427 - 430
  • [47] Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism
    Crane, Alice L.
    Klein, Kathrin
    Zanger, Ulrich M.
    Olson, James R.
    TOXICOLOGY, 2012, 293 (1-3) : 115 - 122
  • [48] Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes
    Villagra, David
    Goethe, John
    Schwartz, Harold I.
    Szarek, Bonnie
    Kocherla, Mohan
    Gorowski, Krystyna
    Windemuth, Andreas
    Ruano, Gualberto
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 427 - 438
  • [49] PREVALENCE OF CYP2D6, CYP2C9 AND CYP2C19 ALLELIC VARIANTS IN A PEDIATRIC SICKLE CELL DISEASE PATIENT COHORT
    Vega, Roger
    Scott, Stuart
    Patel, Niren
    Xu, Hongyan
    Kutlar, Abdullah
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (12) : E19 - E20
  • [50] Frequency of serious adverse drug reactions associated with substrates of the polymorphic enzymes CYP2C9, CYP2C19 and CYP2D6
    Werner, U.
    May, K.
    Drewelow, B.
    Reimann, I. R.
    Hippius, M.
    Hasford, J.
    Thuermann, P. A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2007, 101 (05) : 392 - 392